Business Description
![Cara Therapeutics Inc Cara Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000AIPN.png?14)
Cara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1407551092
Description
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.56 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 0.65 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -17.92 | |||||
Beneish M-Score | -5.65 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -48.4 | |||||
3-Year FCF Growth Rate | -142.7 | |||||
3-Year Book Growth Rate | -40.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 30.75 | |||||
Future 3-5Y Total Revenue Growth Rate | -27.56 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.83 | |||||
9-Day RSI | 55.04 | |||||
14-Day RSI | 50.22 | |||||
6-1 Month Momentum % | -58.28 | |||||
12-1 Month Momentum % | -87.43 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.59 | |||||
Quick Ratio | 4.48 | |||||
Cash Ratio | 4.07 | |||||
Days Inventory | 364 | |||||
Days Sales Outstanding | 121.6 | |||||
Days Payable | 1137.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -27.77 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 74.66 | |||||
Operating Margin % | -941.21 | |||||
Net Margin % | -1010.2 | |||||
FCF Margin % | -736.19 | |||||
ROE % | -189.52 | |||||
ROA % | -103.2 | |||||
ROIC % | -668.56 | |||||
ROC (Joel Greenblatt) % | -1425.52 | |||||
ROCE % | -120.32 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.72 | |||||
PB Ratio | 1.65 | |||||
Price-to-Tangible-Book | 1.65 | |||||
EV-to-EBIT | 0.29 | |||||
EV-to-EBITDA | 0.29 | |||||
EV-to-Forward-EBITDA | -0.04 | |||||
EV-to-Revenue | -2.73 | |||||
EV-to-Forward-Revenue | 0.06 | |||||
EV-to-FCF | 0.37 | |||||
Price-to-Median-PS-Value | 0.05 | |||||
Price-to-Net-Current-Asset-Value | 6.96 | |||||
Earnings Yield (Greenblatt) % | 344.83 | |||||
FCF Yield % | -424.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CARA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cara Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 10.996 | ||
EPS (TTM) ($) | -2.04 | ||
Beta | 0.64 | ||
Volatility % | 104.42 | ||
14-Day RSI | 50.22 | ||
14-Day ATR ($) | 0.026503 | ||
20-Day SMA ($) | 0.34369 | ||
12-1 Month Momentum % | -87.43 | ||
52-Week Range ($) | 0.24 - 2.8831 | ||
Shares Outstanding (Mil) | 54.85 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cara Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cara Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Cara Therapeutics Inc Frequently Asked Questions
What is Cara Therapeutics Inc(CARA)'s stock price today?
The current price of CARA is $0.35. The 52 week high of CARA is $2.88 and 52 week low is $0.24.
When is next earnings date of Cara Therapeutics Inc(CARA)?
The next earnings date of Cara Therapeutics Inc(CARA) is 2024-08-21 Est..
Does Cara Therapeutics Inc(CARA) pay dividends? If so, how much?
Cara Therapeutics Inc(CARA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |